Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback